Journal
BRAIN RESEARCH
Volume 1719, Issue -, Pages 1-10Publisher
ELSEVIER
DOI: 10.1016/j.brainres.2019.05.022
Keywords
Alzheimer's disease; Chemokine; CCR3; beta amyloid; Tau; Cognitive dysfunction
Categories
Funding
- China Postdoctoral Science Foundation [2015M581375]
- National Natural Science Foundation of China [81371395]
- Liaoning Provincial Natural Science Foundation [2015020547]
Ask authors/readers for more resources
The chemokine C-C receptor 3 (CCR3) plays a role in the pathogenesis of Alzheimer's disease (AD). Based on our previous observations that deletion of CCR3 prevented neurodegenerative pathologies in amyloid precursor protein/presenilin 1 (APP/PS1) double-transgenic mice, we hypothesize that CCR3 antagonists may provide therapeutic benefits to AD. To this end, we examined the effect of the brain-penetrable CCR3 antagonist, YM344031, on AD-related pathologies in APP/PS1 double transgenic mice. Treatment of 10-month-old APP/PS1 double-transgenic mice with YM344031 (50 mg/kg, b.i.d.) for two months resulted in dramatic decreases in [beta-amyloid deposition, tau hyperphosphorylation and synaptic loss in the forebrain, significant attenuation of microgliosis and astrogliosis, and marked improvement of spatial learning and memory performance compared with the vehicle-treated mice. These results support CCR3 antagonism as a potential therapeutic strategy for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available